|
시장보고서
상품코드
1973307
난소암 진단 시장 규모, 점유율 및 성장 분석 : 암 유형별, 검사 유형별, 지역별 - 업계 예측(2026-2033년)Ovarian Cancer Diagnostic Market Size, Share, and Growth Analysis, By Cancer Type (Epithelial Tumor Diagnostics, Germ Cell Carcinoma Tumor Diagnostics), By Test Type (Imaging, Blood Test), By Region - Industry Forecast 2026-2033 |
||||||
세계의 난소암 진단 시장 규모는 2024년에 20억 달러로 평가되었고, 2025년 21억 1,000만 달러에서 2033년까지 32억 1,000만 달러로 성장할 전망입니다. 또한, 예측 기간(2026-2033년) CAGR은 5.4%를 나타낼 것으로 예측됩니다.
세계 난소암 진단 시장은 특히 여성에게 심각한 건강 위험을 초래하는 상피성 난소암의 발병률 증가에 큰 영향을 받고 있습니다. 주요 촉진요인으로는 치료 방법의 발전, 암 연구 자금 증가, 건강 의식 증가, 고령 여성 인구 증가 등을 들 수 있습니다. 진단 기술의 혁신은 암을 조기에 발견할 수 있는 방법을 개선하는 길을 열고 있으며, 일반적으로 진행 단계에서 암을 식별하는 현재 진단 방법의 심각한 격차를 해결하고 있습니다. 정부, 연구기관, 의료기관의 조기 진단에 대한 집중적인 노력은 시장 성장을 가속하고 난소암 진단에 새로운 기회를 가져다 줄 것으로 예측됩니다. 전체적으로 이러한 요인들은 종합적으로 난소암 진단 솔루션의 확장을 위한 역동적인 상황을 보여주고 있습니다.
세계 난소암 진단 시장 성장 촉진요인
고령 여성 인구 증가는 전 세계 난소암 진단 시장을 크게 견인하고 있습니다. 고령 여성의 수가 증가함에 따라 난소암 관련 위험도 증가하고 있어 보다 효과적인 진단 솔루션이 요구되고 있습니다. 이러한 인구 통계학적 추세는 스크리닝 및 감지 방법의 발전을 위한 기회를 열어주고 있습니다. 이에 따라 각국 정부는 난소암에 대한 의료 서비스 및 치료 접근성 향상을 위한 정책을 시행하고 있습니다. 이러한 요인들이 결합되어 혁신적인 진단 도구에 대한 수요가 증가하고 있으며, 궁극적으로 전 세계적으로 난소암 진단에 대한 전망을 형성하고 있습니다.
세계 난소암 진단 시장 성장 억제요인
세계 난소암 진단 시장이 직면한 가장 큰 도전은 난소암의 증상에 대한 인식이 널리 부족하다는 점입니다. 많은 사람들이 이러한 증상을 간과하거나 오해하는 경향이 있어 다른 질환과 혼동하는 경우가 많습니다. 이러한 오해가 난소암의 발견과 정확한 진단을 지연시키는 원인이 되고 있습니다. 그 결과, 진행 단계에서의 진단은 병의 심각성을 초래하고, 치료의 선택 폭을 좁혀 환자의 예후에 악영향을 미칠 수 있습니다. 이 문제를 해결하고 조기 발견을 촉진하기 위해서는 인식 제고와 교육 활동 강화가 필수적이며, 궁극적으로 진단 시장의 성장을 가속할 수 있을 것입니다.
세계 난소암 진단 시장 동향
세계 난소암 진단 시장은 암 바이오마커에 대한 이해와 식별을 촉진하는 바이오테크놀러지의 발전에 힘입어 괄목할 만한 성장세를 보이고 있습니다. 혁신적인 검출 기술 및 기기 개발이 진행됨에 따라 새로운 진단 바이오마커에 대한 수익성 높은 기회가 창출되고 있으며, 난소암의 조기 발견 정확도 및 치료 옵션 향상에 기여하고 있습니다. 개인 맞춤형 의료에 대한 인식과 중요성이 높아지면서 이러한 추세는 더욱 가속화되고 있으며, 의료 제공업체가 환자 개개인에 맞는 치료 계획을 제공할 수 있게 되었습니다. 또한, 인공지능(AI)과 머신러닝을 진단 프로세스에 통합하면 환자 치료 결과를 혁신하는 동시에 이 중요한 의료 분야 시장 잠재력을 확대할 수 있을 것으로 기대됩니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 난소암 진단 시장 규모 : 제품 유형별&CAGR(2026-2033)
세계의 난소암 진단 시장 규모 : 진단별&CAGR(2026-2033)
세계의 난소암 진단 시장 규모 : 암유형별&CAGR(2026-2033)
세계의 난소암 진단 시장 규모 : 최종사용자별&CAGR(2026-2033)
세계의 난소암 진단 시장 규모&CAGR(2026-2033)
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.04.01Global Ovarian Cancer Diagnostic Market size was valued at USD 2 Billion in 2024 and is poised to grow from USD 2.11 Billion in 2025 to USD 3.21 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The global ovarian cancer diagnostics market is significantly influenced by the increasing prevalence of ovarian cancer, particularly epithelial ovarian cancer, which poses a significant health risk to women. Key drivers include advancements in treatment methodologies, elevated funding for cancer research, heightened health awareness, and a growing demographic of older women. Innovations in diagnostic technology are paving the way for improved early detection, addressing a critical gap in current diagnostic methods that typically identify cancer at advanced stages. The emphasis on early diagnosis by governments, research institutions, and medical organizations is poised to enhance market growth, offering new opportunities for ovarian cancer diagnostics. Overall, these factors collectively underscore a dynamic landscape poised for expansion in ovarian cancer diagnostic solutions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ovarian Cancer Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ovarian Cancer Diagnostic Market Segments Analysis
Global Ovarian Cancer Diagnostic Market is segmented by cancer type, test type, end user and region. Based on cancer type, the market is segmented into epithelial tumor diagnostics, germ cell carcinoma tumor diagnostics, stromal carcinoma tumor diagnostics and others. Based on test type, the market is segmented into imaging, blood test, biopsy and others. Based on end user, the market is segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ovarian Cancer Diagnostic Market
The rise in the population of elderly women is significantly boosting the global ovarian cancer diagnostics market. As the number of older females increases, so do the associated risks of ovarian cancer, necessitating more effective diagnostic solutions. This demographic trend opens up opportunities for advancements in screening and detection methods. In response to this burgeoning need, various governments implement initiatives aimed at enhancing healthcare services and treatment availability for ovarian cancer. These factors collectively contribute to a growing demand for innovative diagnostic tools, ultimately shaping the landscape of ovarian cancer diagnostics on a global scale.
Restraints in the Global Ovarian Cancer Diagnostic Market
A significant challenge facing the Global Ovarian Cancer Diagnostic market is the widespread lack of awareness regarding the symptoms of this disease. Many individuals tend to overlook or misinterpret these symptoms, leading to confusion with other medical conditions. This misunderstanding contributes to delays in both the detection and accurate diagnosis of ovarian cancer. Consequently, late-stage diagnosis can exacerbate the severity of the illness, complicating treatment options and potentially impacting patient outcomes. Heightened awareness and educational initiatives are essential to address this issue and improve early detection, ultimately fostering growth in the diagnostic market.
Market Trends of the Global Ovarian Cancer Diagnostic Market
The global ovarian cancer diagnostic market is experiencing significant growth, driven by advancements in biotechnology that enhance the understanding and identification of cancer biomarkers. As innovative detection technologies and equipment are developed, they create lucrative opportunities for new diagnostic biomarkers, thus improving accuracy in early detection and treatment options for ovarian cancer. The increasing awareness and emphasis on personalized medicine further catalyze this trend, empowering healthcare providers to offer tailored treatment plans. Additionally, the integration of artificial intelligence and machine learning in diagnostic processes is poised to revolutionize patient outcomes while boosting market potential in this critical healthcare segment.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Technology Analysis
- Case Studies
Global Ovarian Cancer Diagnostic Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Instruments
- Kits & Reagents
- Software & Services
Global Ovarian Cancer Diagnostic Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Imaging Tests
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Other Imaging Tests
- Blood Tests
- CA125
- HER2
- BRCA
- CEA
- ER & PR
- KRAS Mutation
- Other Blood Tests
- Biopsy
- Other Diagnostic Tests
Global Ovarian Cancer Diagnostic Market Size by Cancer Types & CAGR (2026-2033)
- Market Overview
- Epithelial Tumor
- Germ Cell Tumor
- Stromal Cell Tumor
- Other Cancer Types
Global Ovarian Cancer Diagnostic Market Size by End Users & CAGR (2026-2033)
- Market Overview
- Hospitals
- Diagnostic Laboratories
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Cancer Diagnostic Centers
- Research Institutes
Global Ovarian Cancer Diagnostic Market Size & CAGR (2026-2033)
- North America (Product Type, Diagnosis, Cancer Types, End Users)
- US
- Canada
- Europe (Product Type, Diagnosis, Cancer Types, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Diagnosis, Cancer Types, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Diagnosis, Cancer Types, End Users)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Diagnosis, Cancer Types, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthcare GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quest Diagnostics Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina, Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujirebio Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Philips Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hologic
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beckman Coulter
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
